Modular, Automated Synthesis of Spirocyclic Tetrahydronaphthyridines from Primary Alkylamines

Alexander Cresswell (✉ a.j.cresswell@bath.ac.uk)

University of Bath   https://orcid.org/0000-0003-4060-9657

Qiao Cao

University of Bath

Joshua Tibbetts

University of Bath

Gail Wrigley

AstraZeneca

Adam Smalley

UCB

Article

Keywords:

Additional Declarations: There is **NO** Competing Interest.

Modular, Automated Synthesis of Spirocyclic Tetrahydronaphthyridines from Primary Alkylamines

Qiao Cao,[a] Joshua D. Tibbetts,[a] Gail L. Wrigley,[b] Adam P. Smalley,[c] Alexander J. Cresswell*[a]

[a] Department of Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, U.K., E-mail: a.j.cresswell@bath.ac.uk.

[b] Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, U.K.

[c] UCB, 216 Bath Road, Slough, SL1 3WE, U.K.

Abstract: Spirocyclic tetrahydronaphthyridines (THNs) are valuable scaffolds for drug discovery campaigns, but access to this 3D chemical space is hampered by a lack of modular and scalable synthetic methods. We hereby report a fully automated, continuous flow synthesis of α-alkylated and spirocyclic 1,2,3,4-tetrahydro-1,8-naphthyridines ("1,8-THNs"), in addition to their regioisomeric 1,6-THN analogues, from abundant primary amine feedstocks. An annulative disconnection approach based on photoredox-catalysed hydroaminoalkylation (HAA) of halogenated vinylpyridines is sequenced in combination with intramolecular S_NAr N-arylation. To access the remaining 1,7- and 1,5-THN isomers, a photoredox-catalysed HAA step is telescoped with a palladium-catalysed C–N bond formation. Altogether, this provides a highly modular access to four isomeric THN cores from a common set of unprotected primary amine starting materials, using the same bond disconnections. The simplifying power of the methodology is illustrated by a concise synthesis of the spirocyclic THN core of Pfizer's MC4R antagonist PF-07258669, reducing the previous step count by 67%.

Introduction: Bicyclic compounds featuring saturated N-heterocycles fused to (hetero)aromatic units are highly prized in medicinal chemistry,[1] offering a combination of polar functionality, high Fsp³-content, and rigidly disposed groups on the aromatic core that can engage in key interactions with a protein target (e.g., H-bonds).[2,3] Tetrahydronaphthyridines (THNs) are semi-saturated bicycles that ring-fuse a piperidine with a pyridine – these in turn being the two most popular N-heterocycles deployed in small-molecule pharmaceuticals.[4] Positioning of the two THN nitrogen atoms generates eight different structural isomers: four of which (**1a**–**d**) can be considered as CH→N bioisosteres of tetrahydroquinolines (THQs), and the remaining four (structures **2**) as CH→N bioisosteres of tetrahydroisoquinolines (THIQs) (**Scheme 1A**). The substitution of CH units for N atoms in (hetero)aromatic systems can impart orders of magnitude improvements in key physicochemical (e.g., solubility) and pharmacological parameters,[5] and synthetic strategies that could provide facile access to any THN isomer (e.g., **1a**–**d**) would be highly enabling. Without a trivial naming convention for THNs, we shall hereafter refer to structures **1** as "THNs" and their isomeric counterparts **2** as "THINs",[6] by analogy to THQs and THIQs. Amongst other applications,[7] THNs have found use as guanidine mimetics of the arginine binding motif in RGD-binding integrin inhibitors (e.g., **3**).[8] Scaffold morphing of quinolines to THNs can also be an effective tactic to improve aqueous solubility, as exemplified during the development of the FGFR4 selective inhibitor Roblitinib (FGF401) **4** (**Scheme 1B**).[9] Spirocyclisation of fused, semi-saturated N-heterocycles is also emerging as a powerful design strategy for medicinal chemistry. When compared to their flat, all-aromatic counterparts, partial saturation and installation of a spirocycle simultaneously increases Fsp³, reduces structural flexibility, and introduces alternative exit vectors for

access to novel 3D chemical space.[10] In favourable cases, this can lead to greatly enhanced potency, selectivity, solubility, and metabolic stability.[11] For instance, Pfizer have exploited a spirocyclic THN as the core of their MC4R antagonist PF-07258669 **5**, which is currently in phase I clinical trials for the treatment of


Scheme 1

anorexia nervosa (**Scheme 1C**).[12] The spirocycle in **5** was rationally designed to enforce a *cis*-relationship between the N–H bond and the adjacent N(sp²) lone pair, which is the optimal geometry for target binding but opposite to the (*trans*) conformer favoured in solution for the non-constrained analogue.[13]

Despite the many opportunities for structural and physicochemical tuning that THNs can offer, their widespread adoption in early-stage drug discovery has likely been hampered by their poor commercial availability, and the scarcity of THN synthesis approaches that are readily amenable to library generation. Other than the semi-hydrogenation of naphthyridines,[14] which can present regio- and chemoselectivity challenges, several routes to THNs have been devised based on the annulation of 2-aminopyridines. These processes tend to be relatively labour-intensive,[15,16] and whilst catalytic annulations do exist,[17] their functional group tolerance is low. Inverse electron demand, intramolecular, hetero-Diels-Alder reactions of tethered imidazolyl[18] or alkynyl[19] triazines sequenced with N₂ extrusion are also on record for THN synthesis, but the substrate syntheses require multiple steps. Moreover, none of the above approaches are amenable to *spirocyclic* THN synthesis. Another distinct strategy is to form THNs *via* the *N*-arylative cyclisation of γ-pyridyl amines, either by intramolecular Pd-catalysed C–N coupling,[12,20,21] S_NAr reactions,[20,21,22] or Chichibabin reactions.[23] γ-Pyridyl amines **6** can themselves be constructed *via* Sonogashira-hydrogenation sequences,[12,23b] *B*-alkyl Suzuki-Miyaura coupling,[23a] or the S_N2 ring-opening of cyclic sulfamidates **9** with *ortho*-lithiated halopyridines[22] (**Scheme 2A**). Whilst these approaches can enable access to spirocyclic THNs, the chemistry is not well suited to library synthesis, given the meagre commercial availability of α-(di)substituted propargylic amines (**7**), allylic amines (**8**), or γ-hydroxy amines as starting materials. Yu and co-workers have developed a Pd-catalysed γ-C(sp³)–H arylation of primary alkylamines that can access γ-pyridyl amines, and applied this to a single example of THN synthesis, but the amines amenable to this procedure are largely unfunctionalized and have limited commercial availability.[24] Recently, visible-light photoredox-catalysed approaches have been reported by ourselves and Gaunt *et al.*, respectively, for the modular synthesis of γ-aryl primary amines by the C–C bond-forming coupling of readily available primary alkylamines **10**[20] or ketone-derived imines **11**[21] with styrenes. Between these two disclosures, four examples of spirocyclic 1,2,3,4-tetrahydro-1,8-naphthyridine synthesis were showcased, proceeding *via* the S_NAr cyclisation of (isolated) γ-pyridyl amines from the photoredox step.

In this work, we show that photoredox-catalysed hydroaminoalkylation[25] (HAA) of halogenated vinyl pyridines, followed by intramolecular *N*-arylation *via* S_NAr, can be sequenced in continuous flow[26] to enable a fully automated synthesis of α-alkylated and spirocyclic

1,2,3,4-tetrahydro-1,8-naphthyridines ("1,8-THNs") **13**, in addition to their regioisomeric 1,6-THN analogues **14** (**Scheme 2B**). To access the corresponding 1,7- and 1,5-THN isomers – **15** and **16**, respectively – a photoredox-catalysed HAA step can be telescoped with a palladium-catalysed C–N bond formation. Altogether, this provides a highly modular approach to four THN isomers **13–16** from a common set of unprotected primary amine starting materials **10**, using the same bond disconnections.

A. Selected synthetic routes to (spirocyclic) 1,8-THNs

B. This work

Scheme 2

Results & Discussion

Photoredox-catalysed hydroaminoalkylation (HAA) of 2-fluoro-3-vinylpyridine **17** with cyclohexylamine **10a** gives γ-pyridyl amine **18a** in 97% yield, and subjection of this purified material to DIPEA (1.5 equiv) in DMF at 120 °C for 20 h delivers the corresponding THN **13a** in 92% yield *via* intramolecular S_NAr cyclisation.[20] In order to sequence these reactions together in continuous flow, we transferred the chemistry to a Vapourtec R-series flow system equipped with a Uniqsis PhotoSyn LED photoreactor (420 nm LEDs, ~260 W radiant output power, 5-mL reactor coil) and a high-temperature tube reactor (up to 250 °C). As per the batch procedure, the photoredox-catalysed HAA was initially carried out with 2,4,6-tris(diphenylamino)-3,5-difluorobenzonitrile (3DPA2FBN) as the photocatalyst, and tetrabutylammonium azide (Bu₄N⁺N₃⁻) as the hydrogen atom transfer (HAT) catalyst.[27] However, we found that Bu₄N⁺N₃⁻ could be replaced with cheaper and far less hygroscopic sodium azide (NaN₃), which is

A. Automated, continuous flow synthesis of 1,2,3,4-tetrahydro-1,8-naphthyridines **13**

13a, 98%   **13b**, 83%   **13c**, 73%   **13d**, 79%   **13e**, 75%   **13f**, 67% (1:1 dr)

13g, 85%[b]   **13h**, 83%[b]   **13i**, 89%[b]   **13j**, 49% (80%[a,b])   **13k**, 61%[a,b]

13l, 75%[a]   **13m**, 36%[a]   **13n**, 77%[a]   **13o**, 85%[a,b]   **13p**, 53%[a,b]   **13q**, 63%[a]

B. Automated, continuous flow synthesis of 1,2,3,4-tetrahydro-1,6-naphthyridines **14**

14a, 56%[c]   **14b**, 64%[c]   **14c**, 50%[c]   **14d**, 59%[a,c]   **14e**, 46%[a,c]

[a]With 3.0 equiv of amine. [b]Second step carried out at 200 °C. [c]Second step carried out at 220 °C

Scheme 3

soluble in DMF at 0.06 M. For the S$_N$Ar step, a temperature of 180 °C with t_R = 20 min proved sufficient for complete conversion (see Supporting Information). By running both steps in sequence in continuous flow, an overall yield of 98% of spirocyclic THN **13a** could be obtained from 2-fluoro-3-vinylpyridine **17** and cyclohexylamine **10a** as feedstocks (in a 1:1 ratio). This corresponds to a space-time yield (productivity) of 2.20 mmol h^{-1} (445 mg h^{-1}).

With an optimised continuous flow protocol in hand, we next sought to execute a fully automated library synthesis of 'lead-like'[28,29] THN products **13**, using an autosampler to sequentially load different amine substrates into the Vapourtec flow system. The same autosampler also serves as a fraction collector, into which the steady-state solutions of each product **13** are dispensed (**Scheme 3A**). Each run using 1.50 mmol of the vinylpyridine substrate takes approximately 90 min, which corresponds to 16 compounds in a 24 h period, or 40 compounds total over 60 h if all rack positions are utilised. Cyclic primary amines **10a–d** of varying ring sizes were well tolerated, and amine **10e** bearing benzylic C–H bonds also participated smoothly. Various

functionalities including free hydroxyl groups (**13f,o**), ethers (**13g,k**), thioethers (**13h**), carbamates (**13i,j,p**), and imidazoles (**13q**) proved compatible with the process. For amines bearing electronegative atoms attached to the β- or γ-carbon (**10g**–**k,o,p**), a slightly elevated temperature of 200 °C proved necessary in most cases to drive the S$_N$Ar step to completion within the 20 min residence time. Strained four-membered ring substrates 3-amino-*N*-Boc-azetidine **10j** and 3-aminooxetane **10k** proved especially challenging for the photoredox step, on account of their α-C–H bonds being strengthened by ring strain and inductive effects;[27a] amine **10j** for example gave only 49% yield of **13j**, along with 46% of unreacted **10j**. By increasing the stoichiometry of amines **10j** and **10k** to 3 equivalents, however, the valuable spirocyclic THNs **13j** and **13k** could be obtained in 80% and 61% yields, respectively. Non-spirocyclic THNs are also readily accessible *via* this methodology; isopropylamine **10l** was used, for example, to generate α,α-dimethyl-substituted THN **13l** in 75% yield. For α-monoalkylated amines (**10m**–**q**), it proved necessary to use 3.0 equivalents of the amine substrate, to mitigate against the formation of undesired dialkylated products during the photoredox α-C–H alkylation step.[20] As ethylamine **10m** is a gas at ambient

pressure, it was dispensed as a 2.0 M solution in THF, affording the simple α-methylated THN **13m** in 36% yield. Ethanolamine **10o** and *N*-Boc ethylenediamine **10p** also proved to be effective substrates, generating α-hydroxymethyl- and α-aminomethyl-substituted THNs **13o** and **13p**, respectively.

We next sought to extend our automated synthesis protocol to the formation of isomeric 1,2,3,4-tetrahydro-1,6-naphthyridines ("1,6-THNs") **14**, using 4-chloro-3-vinylpyridine **18** as a radical acceptor (**Scheme 3B**). Whilst the chlorinated compound **18** is far easier to access than its 4-fluoropyridine-derived[30] counterpart, the decreased S_NAr reactivity of the C–Cl bond necessitated that the temperature of the flow S_NAr step be raised still further to 220 °C. Under these conditions, a small library of spirocyclic 1,6-THNs **14a–e** could be prepared in 46–64% yield.

To demonstrate the scalability of our THN synthesis in flow, we executed the reaction of 4-aminopiperidine substrate **10i** on gram scale on a 5-mL reactor coil, delivering 1.85 g of spirocyclic THN **13i** in 87% yield (equating to a productivity of 600 mg h^{-1}) (**Scheme 4A**). Whilst these reactions inevitably produce racemic materials, resolution of the THNs *via* chiral preparative HPLC provides convenient access to both enantiomers, as exemplified for THN **13n** on a 520 mg scale (**Scheme 4B**).

A. Gram-scale reaction in flow

B. Resolution of chiral racemic THNs by prep HPLC

Scheme 4

Another important objective was to demonstrate further elaboration of the THN products on the pyridine ring. One strategy, which is especially useful for C(6) functionalisation, is to carry out electrophilic halogenation or catalytic C–H borylation[31] reactions (**Scheme 5A**). In order to access THNs **23** and **25** halogenated *ortho* or *para* to the pyridine nitrogen, we utilised vinyl pyridines **22** and **24**, respectively, with the necessary chloro handles preinstalled. Using this strategy, the C(7)-chloro THN **23** was isolated in 68% yield, and the C(5)-chloro THN **25** in 31% yield

(**Scheme 5B**). The latter isomer was anticipated to be the most challenging, requiring the amine nucleophile to distinguish between a *para*-chloro and an *ortho*-fluoro site of attack during the S_NAr step.[22] Taken together, these strategies enable vector growth from any ring position on the fused pyridine moiety of 1,8-THNs, which is likely to be of significant value for fragment-based drug discovery.[1]

A. C–H functionalisation of the pyridine ring at C(6)

B. Access to other halogenated THN isomers

Scheme 5

Varying the position of the pyridine nitrogen atom in these spirocyclic THN scaffolds is another highly desirable objective from a medicinal chemistry standpoint.[5] Having already demonstrated a fully-automated flow synthesis of 1,8- and 1,6-THNs **13** and **14** from primary alkylamine feedstocks, we were motivated to develop a practical catalytic solution to access 1,7- and 1,5-THN isomers, based on the same photoredox-catalysed HAA disconnection approach. With intramolecular *N*-arylation *via* S_NAr no longer being feasible, we instead opted to carry out this key step using palladium catalysis. Following a flow photoredox HAA of amine **10i** with 3-chloro-4-vinylpyridine **26**, γ-pyridyl amine **27** was isolated in 25% yield. The low yield in this case was traced to extensive polymerization side reactions, for which vinylpyridine **26** seems to be particularly prone. Subsequent cyclisation *via* a Buchwald-Hartwig C–N coupling then gave 1,7-THN **28** in 79% yield (**Scheme 6A**). An analogous sequence using 3-chloro-2-vinylpyridine **29** gave 1,5-THN in an overall 47% yield over the two steps (**Scheme 6B**).

A. Stepwise synthesis of 1,2,3,4-tetrahydro-1,7-naphthyridines

B. Stepwise synthesis of 1,2,3,4-tetrahydro-1,5-naphthyridines

Scheme 6

Finally, we sought to apply our methodology to a concise synthesis of the spirocyclic THN core (**35**) of Pfizer's MC4R antagonist PF-07258669 **5**, which was previously synthesised in 15 total steps (11 steps LLS) (**Scheme 7A**).[12] In our case, starting from commercially available 3-amino *N*-Boc pyrrolidine **32**, a photocatalytic HAA reaction with vinylpyridine **33** in continuous flow gave γ-pyridyl amine **34** (427 mg) in 79% yield. Attempted thermal S$_N$Ar cyclisation of **34** at 220 °C in a high-temperature tubular reactor ($t_R = 20$ min) gave only 22% yield of THN **35**, indicating that the methyl substituent α- to the pyridine nitrogen deactivates this pathway. Fortunately, an intramolecular, palladium-catalysed Buchwald-Hartwig *N*-arylation process (as used in the Pfizer route) proved more efficacious, delivering the spirocyclic THN core **35** in 84% yield (**Scheme 7B**). Taking into account the 3-step synthesis of vinyl pyridine **33** (see Supporting Information), a total step count reduction of 67% is achieved, when compared to the industrial route. This illustrates how dramatically the synthesis of complex spirocyclic amines can be streamlined when using a photoredox annulation strategy from unprotected amines.[27a]

Conclusion: In summary, we have developed a fully automated, continuous flow synthesis of α-alkylated and spirocyclic 1,2,3,4-tetrahydro-1,8-naphthyridines ("1,8-THNs"), in addition to their regioisomeric 1,6-THN analogues, from abundant primary amine feedstocks. An annulative disconnection approach based on photoredox-catalysed hydroaminoalkylation (HAA) of halogenated vinylpyridines is sequenced in combination with intramolecular S$_N$Ar *N*-arylation. To access the remaining 1,7- and 1,5-THN isomers, a photoredox-catalysed HAA step is telescoped with a palladium-catalysed C–N bond formation. Altogether, this provides a highly modular access to four isomeric THN cores from a common set of unprotected primary amine starting materials, using the same bond disconnections. The simplifying power of the methodology is illustrated by a concise synthesis of the spirocyclic THN core (**35**) of Pfizer's MC4R antagonist PF-07258669 (**5**), reducing the previous step count by 67%.

Scheme 7

References

[1] (a) Luise, N.; Wyatt, E. W.; Tarver, G. J.; Wyatt, P. G. A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semi-Saturated Heterobicyclic Fragments. *Eur. J. Org. Chem.* **2019**, 1341–1349; (b) Luise, N.; Wyatt, P. G. Generation of Polar Semi-Saturated Bicyclic Pyrazoles for Fragment-Based Drug-Discovery Campaigns. *Chem. Eur. J.* **2018**, *24*, 10443–10451; (c) Palmer, N.; Peakman, T. M.; Norton, D.; Rees, D. C. Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD). *Org. Biomol. Chem.* **2016**, *14*, 1599–1610; (d) Twigg, D. G.; Kondo, N.; Mitchell, S. L.; Galloway, W. R. D.; Sore, H. F.; Madin, A.; Spring, D. R. Partially Saturated Bicyclic Heteroaromatics as an sp³-Enriched Fragment Collection. *Angew. Chem. Int. Ed.* **2016**, *55*, 12479–12483.

[2] Nadin, A.; Hattotuwagama, C.; Churcher, I. Lead-Oriented Synthesis: A New Opportunity for Synthetic Chemistry. *Angew. Chem. Int. Ed.* **2012**, *51*, 1114–1122.

[3] Roughley, S. D.; Jordan, A. M. The Medicinal Chemist's Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates. *J. Med. Chem.* **2011**, *54*, 3451–3479.

[4] (a) Shearer, J.; Castro, J. L.; Lawson, A. D. G.; MacCoss, M.; Taylor, R. D. Rings in Clinical Trials and Drugs: Present and Future. *J. Med. Chem.* **2022**, *65*, 8699–8712. (b) Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257–10274.

[5] Pennington, L.D.; Moustakas, D. T. The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. *J. Med. Chem.* **2017**, *60*, 3552–3579.

[6] For selected syntheses of "*iso*-THNs" **2**, see: (a) Sierov, D.; Nazarenko, K.; Shvydenko, K.; Shvydenko, T.; Kostyuk, A. Synthetic approaches to tetrahydro-2,7- and -1,6-naphthyridines. *Tetrahedron Lett.* **2020**, *61*, 152194. (b) Jouha, J.; Buttard, F.; Lorion, M.; Berthonneau, C.; Khouili, M.; Hiebel, M.-A.; Guillaumet, G.; Brière, J.-F.; Suzenet, F. Domino Aza-Michael-*ih*-Diels−Alder Reaction to Various 3-Vinyl-1,2,4-triazines: Access to Polysubstituted Tetrahydro-1,6-naphthyridines. *Org. Lett.* **2017**, *19*, 4770−4773. (c) Jackl, M. K.; Kreituss, I.; Bode, J. W. Synthesis of Tetrahydronaphthyridines from Aldehydes and HARP Reagents *via* Radical Pictet−Spenger Reactions. *Org. Lett.* **2016**, *18*, 1713−1715. (d) Sirakanyan, S. N.; Spinelli, D.; Geronikaki, A.; Hovakimyan, A. A.; Noravyan, A. S. *Tetrahedron* **2014**, *70*, 8648−8656. (e) Johnson, R. J.; O'Mahony, D. J. R.; Edwards, W. T.; Duncton, M. A. J. *Org. Biomol. Chem.* **2013**, *11*, 1358−1366. (f) Mailyan, A. K.; Peregudov, A. S.; Dixneuf, P. H.; Bruneau, C.; Osipov, S. N. *J. Org. Chem.* **2012**, *77*, 8518−8526. (g) Zhou, Y.; Porco, J. A., Jr.; Snyder, J. K. *Org. Lett.* **2007**, *9*, 393−396.

[7] For THNs and related structures as kinase hinger binders, see: (a) Milkiewicz, K. L.; Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Cheng, M.; Ghose, A. K.; Roemmele, R. C.; Theroff, J. P.; Underiner, T. L.; Zificsak, C. A.; Dorsey, B. D. Synthesis and structure–activity relationships of 1,2,3,4-tetrahydropyrido[2,3-*b*]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. *Bioorg. Med. Chem.* **2010**, *18*, 4351–4362. For THNs as α-tocopherol antioxidant analogues, see: (b) Nam, T.-g.; Rector, C. L.; Kim, H.-y.; Sonnen, A. F. P.; Meyer, R.; Nau, W. M.; Atkinson, J.; Rintoul, J.; Pratt, D. A.; Porter, N. A. Tetrahydro-1,8-naphthyridinol Analogues of α-Tocopherol as Antioxidants in Lipid Membranes and Low-Density Lipoproteins. *J. Am. Chem. Soc.* **2007**, *129*, 10211−10219.

[8] (a) Slack, R. J.; Macdonald, S. J. F.; Roper, J. A.; Jenkins, R. G.; Hatley R. J. D. Emerging therapeutic opportunities for integrin inhibitors. *Nat. Rev. Drug Discov.* **2022**, *21*, 60–78. (b) Procopiou, P. A.; Anderson, N. A.; Barrett, J.; Barrett, T. N.; Crawford, M. H. J.; Fallon, B. J.; Hancock, A. P.; Le, J.; Lemma, S.; Marshall, R. P.; *et al.* Discovery of (*S*)-3-(3-

(3,5-Dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-l)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic $\alpha_v\beta_6$ Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis. *J. Med. Chem.* **2018**, *61*, 8417–8443.

[9] Fairhurst, R. A.; Knoepfel, T.; Buschmann, N.; Leblanc, C.; Mah, R.; Todorov, M.; Nimsgern, P.; Ripoche, S.; Niklaus, M.; Warin, N. *et al.* Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. *J. Med. Chem.* **2020**, *63*, 12542–12573.

[10] Hiesinger, K.; Dar'in, D.; Proschak, E.; Krasavin, M. Spirocyclic Scaffolds in Medicinal Chemistry. *J. Med. Chem.* **2021**, *64*, 150–183.

[11] (a) Chan, B. K.; Seward, E.; Lainchbury, M.; Brewer, T. F.; An, L.; Blench, T.; Cartwright, M. W.; Chan, G. K. Y.; Choo, E. F.; Drummond, J. *et al.* Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). *ACS Med. Chem. Lett.* **2022**, *13*, 84–91. (b) Velázquez, F.; Chelliah, M.; Clasby, M.; Guo, Z.; Howe, J.; Miller, R.; Neelamkavil, S.; Shah, U.; Soriano, A.; Xia, Y. *et al.* Design and Synthesis of P2−P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors. *ACS Med. Chem. Lett.* **2016**, *7*, 1173–1178.

[12] Garnsey, M. R.; Smith, A. C.; Polivkova, J.; Arons, A. L.; Bai, G.; Blakemore, C.; Boehm, M.; Buzon, L. M.; Campion, S. N.; Cerny, M. *et al*. Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. *J. Med. Chem.* **2023**, *66*, 3195−3211.

[13] The use of spirocyclisation to enforce otherwise unfavourable ligand conformations bears some parallels to the "magic methyl effect", which manifests most strongly in situations where it too biases a particular conformation with strong affinity for the target; see: Leung, C. S.; Leung, S. S. F.; Tirado-Rives, J.; Jorgensen, W. L. Methyl effects on protein−ligand binding. *J. Med. Chem.* **2012**, *55*, 4489−4500.

[14] (a) Wang, W.; Feng, X.; Du, H. Borane-catalyzed metal-free hydrogenation of 2,7-disubstituted 1,8-naphthyridines. *Org. Biomol. Chem.* **2016**, *14*, 6683–6686. (b) Ma, W.; Chen, F.; Liu, Y.; He, Y.-M.; Fan, Q.-H. Ruthenium-Catalyzed Enantioselective Hydrogenation of 1,8-Naphthyridine Derivatives. *Org. Lett.* **2016**, *18*, 2730−2733. (c) Yasuda, N.; Hsiao, Y.; Jensen, M. S.; Rivera, N. R.; Yang, C.; Wells, K. M.; Yau, J.; Palucki, M.; Tan, L.; Dormer, P. G. *et al.* An Efficient Synthesis of an $\alpha_v\beta_3$ Antagonist. *J. Org. Chem.* **2004**, *69*, 1959–1966.

[15] Wijtmans, M.; Pratt, D. A.; Valgimigli, L.; DiLabio, G. A.; Pedulli, G. F.; Porter, N. A. 6-Amino-3-Pyridinols: Towards Diffusion-Controlled Chain-Breaking Antioxidants. *Angew. Chem. Int. Ed.* **2003**, *42*, 4370−4373.

[16] Wang, X.; Yang, A.; Jiang, H.; Jiang, X.; Chen, L.; Zhou, J.; Xu, H.; Song, W.; Wang, X.; Geng, X. Rorγ inhibitor having sulfonyl structure. CN Patent WO 2020108538, June 4, 2020.

[17] (a) Xiong, B.; Li, Y.; Lv, W.; Tan, Z.; Jiang, H.; Zhang, M. Ruthenium-Catalyzed Straightforward Synthesis of 1,2,3,4-Tetrahydronaphthyridines *via* Selective Transfer Hydrogenation of Pyridyl Ring with Alcohols *Org. Lett.* **2015**, *17*, 4054–4057. (b) Hofmann, N.; Homberg, L.; Hultzsch, K. C. Synthesis of Tetrahydroquinolines *via* Borrowing Hydrogen Methodology Using a Manganese PN3 Pincer Catalyst. *Org. Lett.* **2020**, *22*, 7964−7970.

[18] Lahue, B. R.; Lo, S.-M.; Wan, Z.-K.; Woo, G. H. C.; Snyder, J. K. Intramolecular Inverse-Electron-Demand Diels−Alder Reactions of Imidazoles with 1,2,4-Triazines: A New Route to 1,2,3,4-Tetrahydro-1,5-naphthyridines and Related Heterocycles. *J. Org. Chem.* **2004**, *69*, 7171–7182.

[19] (a) Haenel, F.; John, R.; Seitz, G. Trifluormethyl-substituierte, heterocyclisch anellierte Pyridine durch intramolekulare Diels-Alder-Cycloaddition mit inversem Elektronenbedarf. *Arch. Pharm.* **1992**, *325*, 349−352. (b) Seitz, G.; Richter, J. *Chem.-Ztg.* **1989**, *113*, 252−254. (c) John, R.; Seitz, G. 3-Methylthio-5-trifluormethyl-1,2,4-triazin als Edukt zur Synthese heteroanellierter Pyridine durch intramolekulare Diels-Alder-Cycloaddition mit inversem Elektronenbedarf. *Arch. Pharm.* **1989**, *322*, 561−564.

[20] Askey, H. E.; Grayson, J. D.; Tibbetts, J. D.; Turner-Dore, J. C.; Holmes, J. M.; Kociok-Kohn, G.; Wrigley, G. L.; Cresswell, A. J. Photocatalytic Hydroaminoalkylation of Styrenes with Unprotected Primary Alkylamines. *J. Am. Chem. Soc.* **2021**, *143*, 15936–15945.

[21] Blackwell, J. H.; Harris, G. R.; Smith, M. A.; Gaunt, M. J. Modular Photocatalytic Synthesis of α-Trialkyl-α-Tertiary Amines. *J. Am. Chem. Soc.* **2021**, *143*, 15946−15959.

[22] Schrader, T. O.; Zhu, X.; Kasem, M.; Li, S.; Liu, C.; Ren, A.; Wub, C.; Semple, G. Asymmetric syntheses of (*R*)-4-halo-6,6*a*,7,8,9,10-hexahydro-5*H*-pyrazino[1,2-*a*][1,*n*]naphthyridines, important 5-HT2C agonist precursors. *Tetrahedron Lett.* **2018**, *59*, 2030–2033.

[23] (a) Breslin, M. J.; Duggan, M. E.; Halczenko, W.; Hartman, G. D.; Duong, L. T.; Fernandez-Metzler, C.; Gentile, M. A.; Kimmel, D. B.; Leu, C.-T.; Merkle, K. *et al.* Nonpeptide $\alpha_v\beta_3$ antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 4515–4518. (b) Hartner, F. W.; Hsiao, Y.; Eng, K. K.; Rivera, N. R.; Palucki, M.; Tan, L.; Yasuda, N.; Hughes, D. L.; Weissman, S.;

Zewge, D. *et al*. Methods for the Synthesis of 5,6,7,8-Tetrahydro-1,8-naphthyridine Fragments for $\alpha_V\beta_3$ Integrin Antagonists. *J. Org. Chem.* **2004**, *69*, 8723–8730.

[24] Yu and co-workers have developed a Pd-catalysed γ-C(sp³)–H arylation of primary alkylamines that can access γ-pyridyl amines, and applied this to a single example of THN synthesis, but the amines amenable to this procedure are largely unfunctionalized and have limited commercial availability; see: Wu, Y.; Chen, Y.-Q.; Liu, T.; Eastgate, M. D.; Yu, J.-Q. Pd-Catalyzed γ-C(sp³)–H Arylation of Free Amines Using a Transient Directing Group. *J. Am. Chem. Soc.* **2016**, *138*, 14554−14557.

[25] (a) DiPucchio, R. C.; Rosca, S.-C.; Schafer, L. L., Hydroaminoalkylation for the Catalytic Addition of Amines to Alkenes or Alkynes: Diverse Mechanisms Enable Diverse Substrate Scope. *J. Am. Chem. Soc.* **2022**, *144*, 11459–11481. (b) Manßen, M.; Schafer, L. L. Early Transition Metal-Catalyzed Hydroaminoalkylation. *Trends Chem.* **2021**, *3*, 428–429. (c) Trowbridge, A.; Walton, S. M.; Gaunt, M. J. New Strategies for the Transition-Metal Catalyzed Synthesis of Aliphatic Amines. *Chem. Rev.* **2020**, *120*, 2613–2692.

[26] (a) Buglioni, L.; Raymenants, F.; Slattery, A.; Zondag, S. D. A.; Noël, T. Technological Innovations in Photochemistry for Organic Synthesis: Flow Chemistry, High-Throughput Experimentation, Scale-up, and Photoelectrochemistry. *Chem. Rev.* **2022**, *122*, 2752–2906. (b) Brandão, P.; Pineiro, M.; Pinho e Melo, T. M. V. D. Flow Chemistry: Sequential Flow Processes for the Synthesis of Heterocycles. In *Heterocycles: Synthesis, Catalysis, Sustainability, and Characterization*; Brandão, P.; Pineiro, M.; Pinho e Melo, T. M. V. D., Eds.; Wiley-VCH: Weinheim, 2022. (c) Rehm, T. H. Photochemistry in Flow for Drug Discovery. In *Flow Chemistry in Drug Discovery*; Alcazar, J.; de la Hoz, A.; Díaz-Ortiz, A., Eds.; Springer: New York, 2021. (d) Sambiagio, C.; Noël, T., Flow Photochemistry: Shine Some Light on Those Tubes! *Trends Chem.* **2020**, *2*, 92–106. (e) Baumann, M.; Moody, T. S.; Smyth, M.; Wharry, S. A Perspective on Continuous Flow Chemistry in the Pharmaceutical Industry. *Org. Process Res. Dev.* **2020**, *24*, 1802–1813. (f) Rehm, T. H. Flow photochemistry as a tool in organic synthesis. *Chem. Eur. J.* **2020**, *26*, 16952–16974. (g) Gioiello, A.; Piccinno, A.; Lozza, A. M.; Cerra, B., The Medicinal Chemistry in the Era of Machines and Automation: Recent Advances in Continuous Flow Technology. *J. Med. Chem.* **2020**, *63*, 6624−6647. (h) Brandão, P.; Pineiro, M.; Pinho e Melo, T. M. V. D. Flow Chemistry: Towards A More Sustainable Heterocyclic Synthesis. *Eur. J. Org. Chem.* **2019**, 7188–7217. (i) Bogdan; A. R.; Dombrowski, A. W., Emerging Trends in Flow Chemistry and Applications to the Pharmaceutical Industry. *J. Med. Chem.* **2019**, *62*, 6422–6468. (j) Flow Chemistry for the Synthesis of Heterocycles, Sharma, U. K.; Van der Eycken, E. V., Eds.; *Topics in Heterocyclic Chemistry*; Springer: New York, 2018.

[27] (a) Ryder, A. S. H.; Cunningham, W. B.; Ballantyne, G.; Mules, T.; Kinsella, A. G.; Turner-Dore, J.; Alder, C. M.; Edwards, L. J.; McKay, B. S. J.; Grayson, M. N.; Cresswell, A. J., Photocatalytic α-Tertiary Amine Synthesis via C−H Alkylation of Unmasked Primary Amines. *Angew. Chem. Int. Ed.* **2020**, *59*, 14986–14991. (b) Grayson, J. D.; Cresswell, A. J., γ-Amino phosphonates *via* the photocatalytic α-C–H alkylation of primary amines. *Tetrahedron* **2021,** *81*, 131896.

[28] Foley, D. J.; Nelson, A.; Marsden, S. P. Evaluating New Chemistry to Drive Molecular Discovery: Fit for Purpose? *Angew. Chem. Int. Ed.* **2016**, *55*, 13650 – 13657.

[29] Nadin, A.; Hattotuwagama, C.; Churcher, I. Lead-Oriented Synthesis: A New Opportunity for Synthetic Chemistry. *Angew. Chem. Int. Ed.* **2012**, *51*, 1114–1122.

[30] Desai, P. B. Preparation and Stability of 4-Fluoropyridine. *J. Chem. Soc., Perkin Trans. 1* **1973**, 1865–1866.

[31] Preshlock, S. M.; Plattner, D. L.; Maligres, P. E.; Krska, S. W.; Maleczka Jr. R. E.; Smith III, M. R., A Traceless Directing Group for C–H Borylation. *Angew. Chem. Int. Ed.* **2013**, *52*, 12915–12919.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupportingInformation.pdf